Xcout Intel
Zyus Life Sciences Corp
ZYUS Life Sciences Inc. is a Canadian life sciences company listed on the TSX Venture Exchange under the ticker ZYUS. The company is engaged in pharmaceutical research and the development of cannabinoid-based therapeutics and intellectual property.
Subscribe to see Zyus Life Sciences Corp’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Zyus Life Sciences Corp at a glance
Zyus Life Sciences Corp is a pharmaceuticals company headquartered in Canada. Xcout tracks 17 named people at Zyus Life Sciences Corp, including Brent Zettl (President, Chief Executive Officer).
Zyus Life Sciences Corp leadership
- Brent ZettlPresident, Chief Executive Officer
- John EagleActing Chief Financial Officer
- Dr. Julie StakiwChief Medical Officer
- Scott LivingstoneVP of Clinical Research
- Brent ZettlExecutive Officer
- Brett ZettlExecutive Officer
11 more named people on record for Zyus Life Sciences Corp, with roles, board committees and tenure — see the full roster →
Zyus Life Sciences Corp competitors
A few of Zyus Life Sciences Corp's closest competitors — see the full list of competitors and alternatives →
Helus Pharma Inc. advances mental health treatments by developing novel, second-generation therapies, proprietary drug delivery systems, and patent-protected molecules. The company serves the healthcare and pharmaceutical sectors.
Nascent Pharma Holdings, Inc. is a pharmaceutical intellectual property holding company that owns and monetizes patents for high-purity liquid cannabinoid formulations. The company serves the health, wellness, cannabis, and medical industries by licensing its proprietary technology for pain management and neurological disorder treatments.
Mindset Pharma Inc. is a drug discovery and development company based in Toronto, Canada, focused on creating optimized, patentable next-generation psychedelic medicines.
Cannabinoid API Solutions, LLC provides hemp-derived cannabinoid active pharmaceutical ingredients, such as Cannabidiol (CBD) and Cannabigerol (CBG), for the pharmaceutical and nutraceutical industries. The company supplies ultra-pure and natural ingredients tailored for the CBD pharmaceutical market.
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
NYB Holdings Ltd operates an AI-first drug discovery and biotechnology platform that utilizes a large natural compound library and predictive modeling to identify bioactive compounds. The company develops science-backed wellness solutions for nutraceutical applications and advances high-potential drug candidates into preclinical development for the pharmaceutical industry.
Get Zyus Life Sciences Corp's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Zyus Life Sciences Corp in Xcout Intel
- 17 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access